Novartis Diovan Promotions Draw FDA Warning Letter For Diabetes Claims

The MARVAL study cited in the sales materials does not demonstrate that the antihypertensive is effective in preserving renal function, FDA's ad division says. The letter preceded Novartis' unveiling of a hypertension disease awareness campaign.